OncLive TV

Mateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Jason J. Luke, MD, FACP, discusses the role of molecular testing in melanoma.

Yelena Y. Janjigian, MD, discusses the importance of selecting ​an optimal first-line therap​y in gastric cancer.

Kathleen ​A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

Daniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.

Timothy Price, MBBS, DHthSc, FRACP, discusses challenges faced during the CodeBreaK 100 trial in gastrointestinal cancers.

Jamie E. Chaft, MD, discusses the rationale behind the ​OPAL trial in EGFR-mutant non–small cell lung cancer.

Jia Ruan, MD, PhD, discusses treatment considerations in mantle cell lymphoma.

Cathy Eng, MD, FACP, FASCO, discusses the features of high-risk colorectal cancer.

John O. Mascarenhas, MD, discusses emerging agents in myelofibrosis.

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer.

Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.

Robert M. Dean, MD, discusses remaining challenges in diffuse large B-cell lymphoma.

Daniel W. Lin, MD, discusses the importance of biomarker research in prostate cancer.

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses improved sequencing strategies in hepatocellular carcinoma.

Alan P. Z. Skarbnik, MD, discusses treatment strategies for patients with mantle cell lymphoma.

Emily C. Ayers, MD, discusses recent developments in chronic lymphocytic leukemia.

Kirsten ​L. Greene, MD, MAS, FACS, discusse​s the future of personalized therapy in prostate cancer.

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of biomarker testing in gastrointestinal cancers.

Cathy Eng, MD, FACP, FASCO, discusses the role of ​preventive screening in colorectal cancer.

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Allison Winter, MD, discusses the utility of PI3K inhibitors in chronic lymphocytic leukemia.

Leslie M. Randall, MD, MAS, ​discusses the unmet need​s in platinum-resistant ovarian cancer.

Janakiraman Subramanian, MD, discusses the potential utility of dostarlimab in ​previously treated patients with non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, discusses limitations with immunotherapy in non–small cell lung cancer.